findmyKOL
Clinical trialNCT01656252TerminatedPhase 1/PHASE2Interventional

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

SponsorPrECOG, LLC.Enrollment15Acute Myeloid Leukemia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Patients with Acute Myeloid Leukemia (AML) in complete remission will receive eltrombopag while undergoing consolidation chemotherapy with high-dose cytarabine. Eltrombopag may help increase the number of platelets during chemotherapy and may help prevent the risk of bleeding. Phase I will study the side effects, best dose and platelet effects of eltrombopag when given with consolidation chemotherapy. After the maximum safe and tolerated dose and schedule is found in Phase I, the study will proceed to Phase II. Phase II will confirm the dose and schedule of eltrombopag identified in Phase I that can increase platelet counts in patients receiving consolidation therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Massachusetts Worcester

    Worcester, Massachusetts, United States

  • Mayo Clinic, Rochester

    Rochester, Minnesota, United States

  • University Hospitals Case Medical Center

    Cleveland, Ohio, United States

  • Penn State Hershey Cancer Institute

    Hershey, Pennsylvania, United States

  • Vanderbilt University

    Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Phase I- Cytarabine & EltrombopagPhase II- Sequence APhase II- Sequence B
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2012
Primary completion
31 Mar 2016
Completion
31 Mar 2016
Last update posted
3 Nov 2020
Registered enrollment
15
Registry id
NCT01656252
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.